7,165 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Bought by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 7,165 shares of the company's stock, valued at approximately $447,000.

Other institutional investors have also made changes to their positions in the company. Clear Creek Financial Management LLC purchased a new stake in TransMedics Group in the 4th quarter worth about $352,000. Vaughan Nelson Investment Management L.P. lifted its position in shares of TransMedics Group by 9.9% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company's stock worth $22,547,000 after purchasing an additional 32,605 shares in the last quarter. Baillie Gifford & Co. boosted its holdings in shares of TransMedics Group by 14.9% during the fourth quarter. Baillie Gifford & Co. now owns 269,836 shares of the company's stock worth $16,824,000 after purchasing an additional 34,947 shares during the period. State of Michigan Retirement System purchased a new position in TransMedics Group during the fourth quarter valued at approximately $6,734,000. Finally, Charles Schwab Investment Management Inc. increased its stake in TransMedics Group by 2.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company's stock valued at $42,656,000 after buying an additional 6,634 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Stock Performance

Shares of TMDX traded down $1.86 during mid-day trading on Friday, hitting $68.58. The company's stock had a trading volume of 612,338 shares, compared to its average volume of 1,322,479. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37. The stock's 50-day moving average is $69.11 and its two-hundred day moving average is $88.08. The firm has a market capitalization of $2.31 billion, a PE ratio of 72.96 and a beta of 2.12. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

Remove Ads

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Oppenheimer restated an "outperform" rating and set a $125.00 price target on shares of TransMedics Group in a report on Tuesday, December 3rd. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $75.00 target price (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a report on Wednesday. Robert W. Baird lowered their price target on TransMedics Group from $150.00 to $120.00 and set an "outperform" rating for the company in a research note on Wednesday, December 11th. Finally, Piper Sandler cut their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an "overweight" rating on the stock in a research report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $122.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.